Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02588274
Other study ID # 2015S102
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 2015
Est. completion date November 2017

Study information

Verified date February 2019
Source Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) affects many adult men worldwide. So far, available therapies offer little or no proven benefit to CP/CPPS. The investigators design and implement this study is to assess efficacy of acupuncture therapy performed in the CP/CPPS .


Description:

This study is a multi-center, placebo-controlled, randomized trial comparing acupuncture and placebo needle among patients with CP/CPPS, which will be conducted in Guang'anmen Hospital of China Academy of Chinese Medical Sciences and Yantai Chinese Medicine Hospital from November 2015 to May 2017. 68 patients will be recruited in total through the advertisements spreading by newspaper, television and internet. After participants have completed a baseline evaluation and meet the selection criteria, one professional statistician uninvolved with treatment and data collection will assigns the participants by using a computer generated, blocked random allocation sequence randomly and acupuncturist will be blinded to the process of randomized assignment.Treatment group will use acupuncture and control group will use placebo needle, for treatment, Zhongliao (BL 33), Shenshu (BL 23), Guiyang (BL 35), Sanyinjiao (SP 6) acupuncture points will be used, the treatment sessions are 24 weeks after baseline, 3 times a week and each time the patients will accept a 30 minutes treatment, to control group, participants will receive placebo needle treatment at the same acupuncture points and the duration and frequency of sessions are same to the real acupuncture group. The primary outcome measure of this study is the decreasing in (National Institutes of Health Chronic Prostatitis Symptom Index) NIH-CPSI total score from baseline to week 8, and secondary outcomes include NIH-CPSI sub scales at week, (International Prostate Symptom Score) IPSS total score, Global response assessment, expectation degree and satisfaction degree. The first three secondary outcomes will be measured at 4,8,20 and 32 weeks, expectation degree will be measured at baseline, and the satisfaction degree will be measure at 8, 20, 32 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 68
Est. completion date November 2017
Est. primary completion date May 2017
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

1. History of pain perceived in the region of the prostate and absence of other lower urinary tract pathology for a minimum of 3 out of the past 6 months. In addition, associated lower urinary tract symptoms, sexual function, psychological factors should be addressed.

2. Age 18 to 50 years

3. NIH Chronic Prostatitis Symptom Index (NIH-CPSI) total score= 15 (scale 0-43, and 0 means no symptom).

Exclusion Criteria:

1. Other urologic disease (for example, acute prostatitis, bacterial prostatitis, benign prostatic hyperplasia, prostate cancer, urinary tuberculosis, urinary tract infection)

2. Serious or acute diseases with heart, liver, kidney and blood system.

3. Patients who had received acupuncture or medication (including alpha-blockers or pain killers) treatment in the week prior to the baseline assessment

4. Patients without telephone number who cannot be connected during the follow-up

Study Design


Intervention

Device:
Acupuncture
Acupuncture is one of the oldest standardized neuromodulatory therapies. The method of acupuncture treatment involves the insertion of needles in acupuncture points according to a system of channels and meridians. The needles are stimulated by manual manipulation, electrical stimulation or heat. The general theory of acupuncture is based on the premise that there are patterns of energy flow through the body that are essential for health. Disruptions of this flow are believed to be responsible for disease. Acupuncture may correct imbalances of flow at identifiable points close to the skin.
placebo needle
Placebo needle is a type of control without skin penetration based on the application of placebo needles with blunt needle tips.

Locations

Country Name City State
China Guang'anmen Hospital, China Academy of Chinese Medical Science Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary NIH-CPSI total score and change from baseline baseline, week 1-8
Secondary NIH-CPSI subscales score Baseline, week 4,8,20,32
Secondary NIH-CPSI total score in follow-up week 20,32
Secondary IPSS total score and change from baseline baseline, week 4,8,20,32
Secondary Global response assessment improvement week 4,8,20,32
Secondary expectations degree The expectations that acupuncture might help participants CP/CPPS at baseline. This scale includes two brief questions to investigate whether patients believe acupuncture treatment and if acupuncture may help CP/CPPS. The investigators designed this scale and the investigators want to explore the impact of variable that are potentially associated with placebo effects, namely will participants' expectations be treatment effect modifier? baseline
Secondary Degree of satisfaction The investigators designed this scale, which include 5 grades answer from 0 to 4, means "not at all" "a little" "Quite satisfied" "satisfaction" "very satisfaction"and the investigators want to use this to test blinding of participants. week 8,20,32
See also
  Status Clinical Trial Phase
Completed NCT02898220 - Trans-MAPP II Study of Urologic Chronic Pelvin Pain
Recruiting NCT05868668 - Efficacy of Low-intensity Shockwave vs Radial Wave for Treatment of Erectile Dysfunction and Pelvic Pain N/A
Withdrawn NCT03027076 - Microbiome of Urologic Chronic Pelvic Pain Syndrome N/A
Completed NCT00922012 - Efficacy of Electromagnetic Stimulation Therapy for Chronic Prostatitis and Chronic Pelvic Pain Syndrome N/A
Completed NCT00434343 - Physical Therapy Trial for Pelvic Pain N/A
Completed NCT05890235 - Efficacy and Safety of Ningmitai Capsule in Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome Phase 4
Recruiting NCT03641807 - Different Modes of Assessment on Acupuncture Effect on Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome N/A
Recruiting NCT04976751 - Real World Study on the Application of Appropriate Electrophysiological Technology in the Diagnosis and Treatment of Andrology Diseases in Northwest China Phase 1
Recruiting NCT06299683 - Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment N/A
Completed NCT01843946 - Clinical Efficacy of Roxithromycin in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome N/A
Terminated NCT00301405 - Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain Phase 2
Not yet recruiting NCT06287970 - TaVNS Improves the Symptoms of Patients With Moderate to Severe CP/CPPS N/A
Completed NCT01738464 - Microbiomes of Pelvic Pain
Completed NCT03543761 - Low-intensity Shockwave Therapy for Non-bacterial Prostatitis/Pelvic Pain Syndrome N/A
Completed NCT02711943 - Non Interventional Study of Levofloxacin in Chronic Prostatitis N/A
Completed NCT04275297 - Optimizing Psychosocial Treatment of Interstitial Cystitis/Bladder Pain Syndrome N/A
Completed NCT02514265 - Trans-MAPP Symptom Patterns Study (SPS)
Completed NCT05378646 - Efficiency and Safety of the Drug Ingaron (Interferon-gamma Human Recombinant) in the Treatment of Chronic Prostatitis Phase 3
Recruiting NCT04128280 - Multi-center Clinical Observation of a New Treatment Method Based on the Pathogenesis of Obstructive Prostatitis N/A
Recruiting NCT03629769 - Effects of Proxelan Somministration in Patients With Chronic Prostatitis Phase 3